Contribute Try STAT+ Today

Top of the morning to you, and a fine one it is. Sunny skies and delicious cool breezes are enveloping the Pharmalot campus this morning, where the birds are chirping, the insects are flitting, and the official mascot is snoozing. This provides an opportunity to fire up the trusty coffee kettle and brew a few cups of stimulation. Today we fancy salted caramel mocha. And what are you having? While you made a decision, dig in to the latest items of interest. A little stimulation is a good thing, yes? Have a great day and do keep in touch …

Johnson & Johnson (JNJ) said that a large, global study showed its Covid-19 vaccine is more effective when given as a two-dose regimen, and that other data indicate the efficacy of the vaccine does not wane, STAT writes. The two-dose regimen prevented 75% of moderate to severe Covid cases in all countries where it was tested — and 94% of such cases in the U.S., where the vaccine probably had to grapple with fewer variants of the virus. Importantly, the two-dose regimen was 100% effective against severe disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment